MDA
3,4-methylenedioxyamphetamine
Viewing r1 — Apr 24, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
MDA (3,4-methylenedioxyamphetamine) — Sass, Sally, Love Drug — is a synthetic empathogen of the substituted amphetamine class. It is the parent compound of MDMA, predating it by decades. MDA floods serotonin, dopamine, and norepinephrine into the brain while also directly activating serotonin receptors — the same ones classical psychedelics target.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
First synthesized in 1910,[2] MDA was tested as an antidepressant and appetite suppressant in the 1950s before spreading through 1960s counterculture as the "Love Drug." Its scheduling in 1970[3] accelerated MDMA's rise — the less-restricted derivative that replaced it on the street. Today MDA remains prohibited in most countries with no approved medical use, occasionally surfacing under the names Sass or Molly.
Subjective effects include empathogenic warmth, emotional openness, stimulation, wakefulness, and genuine closed-eye hallucinations — geometry, formed imagery, and complex scenes.[4] The experience layers psychedelic depth over MDMA-like closeness, with stronger stimulation than either — a combination that sets MDA apart from pure empathogens and classical psychedelics alike.[5] Anxiety, elevated fear, and cardiovascular strain are characteristic unsought effects, appearing even in controlled settings.[5]
MDA does not produce physical dependence, but it is more neurotoxic than MDMA — the liver converts it into compounds that selectively destroy serotonin nerve terminals.[6][7] Heat amplifies this damage sharply: even small temperature increases make neurotoxicity substantially worse,[8] making hot environments the most dangerous context. Human toxicity thresholds are unknown — most data come from animals, with a 2026 controlled trial providing the best available human evidence.[5]
History[edit]
Discovery
MDA was first synthesized in 1910 by German chemists G. Mannish and W. Jacobson,[2] years before its better-known derivative MDMA. Animal studies in 1939 revealed stimulant activity, and the first human trials began in 1941, initially exploring Parkinson's disease.[2]
Clinical and cultural significance
Between 1949 and 1957, Smith, Kline, and French tested MDA in over 500 subjects as an antidepressant and appetite suppressant, briefly marketing it as "Amphedoxamine".[2] Recreational use surfaced in the early 1960s — MDA earned the street name "Love Drug" for its mix of empathogenic warmth and hallucinogenic effects.[2] In 1986, David Nichols coined the term "entactogen" — literally "touching within" — to describe the class MDA helped define.[9]
Prohibition and modern use
MDA was scheduled in 1970 in the United States,[3] directly accelerating the rise of MDMA, which remained legal for another fifteen years. No clinical trials have investigated MDA as a primary therapeutic — the most significant modern data comes from a 2026 head-to-head comparison with MDMA.[5]
The name "Sass" derives from sassafras oil, the natural source of safrole from which MDA has historically been synthesized.[10] "Sally" follows as a feminized variant. Among the MDxx compounds, MDA is the progenitor: first synthesized, first scheduled, and the template from which MDMA and others were derived.
Chemistry[edit]
Structural class
MDA belongs to the substituted amphetamine class and is the parent compound of the MDxx series. Its defining structural feature is a 3,4-methylenedioxy ring fused onto the phenyl group of an amphetamine backbone. It is the N-desmethyl structural analog of MDMA — the two molecules differ by a single methyl group on the nitrogen atom, and that one-atom difference gives MDA direct psychedelic receptor activity that MDMA lacks.
Molecular properties
| Molecular formula | C₁₀H₁₃NO₂ |
| Molecular weight | 179.22 g/mol |
The methylenedioxy ring is also present in safrole, a natural product from which MDA has historically been synthesized in clandestine settings.[10]
Pharmacology[edit]
Mechanism of action
MDA works by reversing the serotonin, dopamine, and norepinephrine transporters, flooding all three into the synapse at once — with especially potent effects on norepinephrine[1] and stronger dopamine release than MDMA.[11] It also directly activates serotonin's psychedelic receptor, the same one targeted by LSD and psilocybin.[1] Animal studies confirm MDA substitutes for both LSD and amphetamine,[12][13] reflecting this dual mechanism.
Pharmacokinetics
After an oral dose, effects begin around 42 minutes, peak near 2 hours, and last approximately 6 hours, with a plasma half-life of 8.4 hours — slightly longer than MDMA's under identical conditions.[5] The liver processes MDA primarily through CYP2D6 enzymes.[14][15] Like MDMA, MDA likely inhibits its own breakdown: doubling the dose can more than double blood concentrations, making dose escalation disproportionately dangerous. CYP2D6 inhibitors like fluoxetine and paroxetine slow this metabolism further, raising blood levels and toxicity risk.[16]
Neurotoxic metabolites
The liver converts MDA into a compound called alpha-methyldopamine, which travels to the brain and destroys serotonin nerve terminals.[7][17] MDA injected directly into the brain does not cause this damage — liver processing is required.[7] Every person who takes MDMA is also exposed to MDA: the body converts roughly 3–5% of MDMA into MDA,[18][19] along with its toxic metabolites.
Neuroscience[edit]
Where it acts
MDA's serotonin release quiets the brain's threat-detection center (the amygdala) and strengthens connections to the prefrontal cortex[11] — the circuit underlying empathogenic warmth. Its direct activation of the psychedelic serotonin receptor disrupts normal sensory filtering,[1][20] producing the closed-eye geometry and formed imagery documented in controlled studies.[4] Dopamine[11] and norepinephrine[1] drive the stimulant layer — confirmed as stronger than MDMA's in human trials.[5]
Why it matters
MDA is a natural test case for what happens when empathogenic and psychedelic mechanisms run simultaneously. The psychedelic receptor action loosens the brain's top-down filtering, letting raw sensory signals have more influence on perception — MDA's documented disruption of contour integration and object recognition[4] fits this model. The emotional intensification from monoamine release may amplify the felt significance of those perceptual shifts.
No neuroimaging studies of MDA in humans have been published. Key unknowns include whether the dual mechanism produces greater brain plasticity than either MDMA or classical psychedelics alone, and whether MDA's greater preclinical neurotoxicity translates to measurable serotonin damage in human users. MDA also shows unusual bidirectional effects on GABA receptors,[21] the significance of which remains unexplored.
Subjective Effects[edit]
MDA produces stimulant energy, empathogenic warmth, and psychedelic perception simultaneously — not in sequence. The experience is defined by this three-way combination: the physical drive of a stimulant, the emotional openness of an empathogen, and at common doses and above, genuine visual hallucinations.[4]
MDA sits between MDMA and classical psychedelics like LSD. It shares MDMA's warmth and social drive, but adds visual depth MDMA lacks — closed-eye patterns and formed imagery are real features, not artifacts. The stimulant component is stronger than either, and fear can surface even in calm settings.[5]
Effect Grid
At common doses (60–100 mg oral), all three pharmacological dimensions are fully expressed. Entactogenic effects — empathy enhancement, emotional openness, increased desire for social connection — are prominent. Stimulation is marked: wakefulness, thought acceleration, and physical energy. The psychedelic component produces color enhancement, visual brightening, and, in approximately 50% of individuals, closed-eye visions including geometric patterns and formed imagery.
Bruxism (jaw clenching), pupil dilation, sweating, and elevated heart rate are typical. Temperature dysregulation becomes clinically relevant — overheating risk increases, especially in warm environments or during physical exertion.
Total duration is approximately 5–7 hours, with peak effects around 1.5–3 hours post-ingestion. Sleep is unlikely for 8+ hours. The experience demands a full evening's commitment.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual haze / noise · Tracers · Sleep-transition hallucinations · After-images · Brightness alteration · Color alteration · Geometry · Light sensitivity · Sound sensitivity · Symmetrical texture repetition · Auditory distortion · Depth perception distortion · Spatial disorientation · Synesthesia · Visual breathing · Visual drifting · Peripheral misidentification · Environmental patterning · Peripheral vision distortion · Perspective distortion · Proprioceptive distortion · Visual diffraction · Visual morphing · Internal hallucinations · Object transformations · External hallucinations
Brightness alteration · Color alteration · Geometry · Light sensitivity · Sound sensitivity · Symmetrical texture repetition · Auditory distortion · Depth perception distortion · Spatial disorientation · Synesthesia · Visual breathing · Visual drifting · Peripheral misidentification · Environmental patterning · Peripheral vision distortion · Perspective distortion · Proprioceptive distortion · Visual diffraction · Visual morphing · Internal hallucinations · Object transformations · External hallucinations
Pupil dilation · Insomnia · Excessive sweating · Dehydration sensation · Body high · Dry mouth · Physical fatigue · Spontaneous body sensations · Bruxism · Bodily lightness · Tactile euphoria · Tingling / electric sensations · Sexual arousal enhancement · Muscle tension · Heart rate perception changes · Motor control impairment · Nausea · Nystagmus (eye wobbles) · Restlessness · Vasoconstriction · Vibrations / buzzing · Brain zaps · Dizziness · Sexual arousal suppression · Increased urination · Body schema distortion · Yawning · Motor control enhancement · Seizure threshold reduction
Dehydration sensation · Body high · Dry mouth · Physical fatigue · Spontaneous body sensations · Bruxism · Bodily lightness · Tactile euphoria · Tingling / electric sensations · Sexual arousal enhancement · Muscle tension · Heart rate perception changes · Nausea · Nystagmus (eye wobbles) · Restlessness · Vasoconstriction · Vibrations / buzzing · Brain zaps · Dizziness · Sexual arousal suppression · Increased urination · Body schema distortion · Yawning · Motor control enhancement · Seizure threshold reduction
Openness enhancement · Immersion enhancement · Thought acceleration · Novelty enhancement · Motivation suppression · Introspection enhancement · Pattern recognition enhancement · Creativity enhancement · Motivation enhancement · Humor enhancement · Cognitive impairment · Suggestibility enhancement · Thought connectivity · Focus enhancement · Thought disorganization · Thought deceleration · Confusion
Novelty enhancement · Motivation suppression · Introspection enhancement · Pattern recognition enhancement · Creativity enhancement · Motivation enhancement · Humor enhancement · Cognitive impairment · Thought connectivity · Focus enhancement · Thought disorganization · Thought deceleration · Confusion
Anhedonia · Anxiety suppression · Irritability · Catharsis · Emotional lability · Anxiety · Dysphoria · Suicidal ideation
Catharsis · Emotional lability · Anxiety · Dysphoria
Emotional susceptibility · Communication enhancement · Flow state · Derealization · Craving · Boundary dissolution
Craving · Boundary dissolution
Timeline
First alerts emerge 30-60 minutes after ingestion: a subtle shift in mood, mild warmth in the chest, and faint stimulation. Most individuals notice the transition clearly by 40 minutes.
Effects build steadily over 30-60 minutes. Empathogenic warmth, increasing stimulation, and the first visual brightening develop in parallel. Nausea or stomach unease is possible during this phase.
Full expression of the MDA triad: entactogenic openness, pronounced stimulation, and psychedelic visual effects including closed-eye visions in susceptible individuals. Emotional intensity is maximal. Bruxism, pupil dilation, and sweating are prominent.
Intensity gradually recedes from peak levels but remains clearly psychoactive. Stimulation persists while entactogenic and visual effects soften. Conversation and social engagement often increase as the overwhelming quality diminishes.
Effects taper over 1-1. 5 hours. Stimulation fades last, leaving residual wakefulness and mild mood elevation.
Residual wakefulness and mild mood changes persist for 2-4 hours beyond the main experience, consistent with MDA's 8. 4-hour plasma half-life exceeding its 6. 1-hour subjective duration.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 7 days
- Physical
- Negligible
- Psychological
- Low
- Compulsive redosing
- Low
- Dose escalation
- Low
- Cross-tol.
- MDMA · 5-HT psych. · amphetamines
Toxicity
Serotonergic neurotoxicity
MDA causes greater destruction of serotonin nerve terminals than MDMA at equivalent doses.[6] The damage is not from MDA itself — the liver processes MDA into toxic byproducts that travel to the brain and kill serotonin wiring.[7][17]
Temperature is a critical amplifier. Even a small rise in ambient temperature (as little as 2°C) dramatically worsens serotonin neurotoxicity.[8] Hot environments — clubs, dance floors, festivals — substantially increase the risk of permanent serotonergic damage. All direct neurotoxicity data come from animal models.
Cardiovascular toxicity
MDA raises blood pressure more than any other MDxx compound, acting through direct stimulation of epinephrine receptors.[22] In animal studies it produced the sharpest blood pressure spikes, reflex heart rate slowing, and subsequent overheating.[22]
Acute lethality
No human lethal dose has been established. Human fatalities involving amphetamine-class compounds most commonly involve heart and lung failure, overheating, and physical trauma — most victims male and under 25.[23]
Psychological risks
A controlled trial found MDA produced significantly greater fear and "bad drug effects" than MDMA at comparable doses.[5] This elevated anxiety potential is likely driven by the combination of psychedelic receptor activation and strong adrenaline-like effects.
MDA's psychedelic receptor activity places it in the same risk category as classical psychedelics for triggering acute psychotic episodes in predisposed individuals.inferred No MDA-specific data on substance-induced psychosis or HPPD (HPPD) exist.
Tolerance and dependence
No MDA-specific tolerance or dependence studies have been published. MDA's greater stimulant burden compared to MDMA[5] suggests compulsive use is possible through dopamine-driven reinforcement. Physical dependence and withdrawal have not been characterized.
Drug interactions
Serotonergic agents
Combining MDA with any drug that raises serotonin — MAOIs, SSRIs, SNRIs, serotonergic painkillers, triptans, St. John's wort — risks dangerous overheating, muscle rigidity, uncontrollable muscle jerking, and organ failure.[24]
MAOIs prevent the body from breaking down the serotonin, dopamine, and norepinephrine that MDA releases. The combination can cause fatal serotonin overload and dangerous blood pressure spikes. This interaction is potentially fatal.
Tramadol blocks serotonin and norepinephrine reuptake,[25] creating conditions for severe serotonin syndrome when combined with MDA's massive serotonin release.safety citation needed
MDMA
Combined use of MDA and MDMA adds serotonergic effects together. Both are serotonin releasers; combining them increases overheating risk, cardiovascular stress, and serotonin toxicity risk.
CYP2D6 inhibitors
Fluoxetine, paroxetine, quinidine, bupropion, and other CYP2D6 inhibitors slow MDA's metabolism, raising blood levels and toxicity risk substantially.[16]
Norepinephrine reuptake inhibitors
Norepinephrine reuptake inhibitors such as reboxetine block norepinephrine release, blunting both stimulant effects and dangerous cardiovascular effects.[26] This is an antagonistic interaction.
Contraindications
Heart conditions and high blood pressure: MDA is the most potent blood pressure-raising agent in the MDxx series.[22] Pre-existing cardiovascular disease, uncontrolled high blood pressure, and structural heart abnormalities are absolute contraindications.
Psychotic disorders and bipolar disorder: MDA's psychedelic receptor activity can precipitate psychotic episodes in predisposed individuals. Personal or family history of psychosis, schizophrenia, or bipolar disorder I is an absolute contraindication.inferred
Liver impairment: Reduced liver function slows MDA clearance,[14] raising blood levels and extending duration and toxicity risk.
MAOIs: Absolute contraindication. Potentially fatal serotonin overload and blood pressure crisis.
SSRIs/SNRIs: Relative contraindication. SSRIs reduce empathogenic effects while retaining residual serotonin toxicity risk.
Tramadol and serotonergic painkillers: Absolute contraindication.[25][24]
Pregnancy and breastfeeding: No reproductive toxicity data specific to MDA exist. Given its potent stimulant and serotonergic activity, use during pregnancy is absolutely contraindicated.inferred
Harm Reduction[edit]
Forms & Identification
MDA is most commonly encountered as a white to off-white powder or crystalline substance — the hydrochloride salt — and is sometimes pressed into tablets. It is routinely sold as "Sass," "Molly," or confused with MDMA, making reagent testing essential before every use.
MDA and MDMA produce different color reactions with Marquis and Simon's reagents, allowing differentiation. Because MDA's neurotoxic and cardiovascular risks exceed MDMA's, knowing which compound is present changes the risk calculation meaningfully. Purity varies widely in unregulated supply. MDA's dose-response curve is steep and its metabolism is nonlinear — small actual dose increases can produce disproportionately large increases in blood concentration.
Guidelines
- Test every dose with at least Marquis and Simon's reagents to confirm substance identity and differentiate from MDMA
- Start low. MDA's nonlinear metabolism means doubling the dose more than doubles blood levels. First-time users should begin at the lower end of the common dose range
- Control temperature. Stay in cool environments. Avoid crowded, hot venues. Take breaks from physical activity. Overheating is the single most modifiable risk factor for serotonergic neurotoxicity[8]
- Hydrate steadily but avoid overhydration — sip water regularly rather than drinking large volumes at once
- Have a sitter if the psychedelic component is unfamiliar. MDA's hallucinogenic effects can be disorienting and anxiety-provoking
- Do not redose. Acute tolerance develops quickly, and redosing increases neurotoxicity risk without proportionally extending the desired experience
- Space use widely. The MDxx class requires extended intervals for serotonin system recovery. Minimum recommended spacing is 6–8 weeks, though longer is safer
Set & Setting
MDA's dual empathogenic-psychedelic character makes environment and psychological preparation more consequential than with MDMA alone. The 2026 controlled trial documented elevated fear and bad drug effects even in clinical settings[5] — anxiety can surface regardless of preparation.
A calm, temperature-controlled environment is especially important: ambient heat dramatically amplifies neurotoxicity.[8] Genuine hallucinations — closed-eye geometry, formed images, complex scenes[4] — are expected at common doses and above. These are not signs of a medical emergency.
Aftercare & integration. The days following MDA use may include low mood, fatigue, irritability, and difficulty concentrating — driven by temporary serotonin depletion. These effects typically resolve within 3–5 days. Adequate sleep, nutrition, and light physical activity support recovery. Avoid other serotonergic substances during this period.
MDA's psychedelic component can produce meaningful or challenging psychological material — vivid imagery, emotional insights, or distressing experiences. Journaling, conversation with trusted people, or a session with a psychedelic-informed therapist can help process difficult content. Persistent anxiety, depersonalization, or visual disturbances lasting more than two weeks warrant professional evaluation.
Recovery & Support
MDA does not produce physical dependence, but patterns of repeated use can develop — particularly where stimulant and empathogenic effects serve as emotional coping tools. Escalating frequency despite awareness of neurotoxic risk is a warning sign. Support options include psychedelic integration circles, harm reduction organizations (DanceSafe, The Loop), SMART Recovery, and substance use counselors familiar with club drugs and psychedelics.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
An MDA experience can be uncomfortable without being dangerous. Signs that require immediate help: chest pain or pressure, seizure, loss of consciousness, body temperature hot to the touch through clothing, rigid or jerking muscles, confusion severe enough to prevent communication, or uncontrollable panic with self-harm risk.
Immediate steps:
- 1. Call emergency services if any of the above signs are present
- 2. Move the person to a cool, quiet area
- 3. Remove excess clothing and apply cool water to skin if overheating is suspected
- 4. Place unconscious but breathing individuals in the recovery position (on their side)
- 5. Do not restrain unless there is immediate danger of self-harm
- 6. Do not induce vomiting
What to tell the dispatcher:
State the substance (MDA or "an MDMA-like stimulant"), the amount if known, the time taken, and current symptoms — particularly body temperature, consciousness level, and any seizure activity. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
MDA is internationally controlled under Schedule I of the United Nations Convention on Psychotropic Substances (1971), preceding the scheduling of MDMA by over a decade.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Classified in 1970; no accepted medical use, high abuse potential[3] |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Maximum penalty for supply: life imprisonment; possession: 7 years[2] |
| Canada | Controlled (CDSA)citation needed | Classification requires verification; secondary sources cite Schedule III but this may be erroneous |
| Australia | Schedule 9 (Standard for the Uniform Scheduling of Medicines and Poisons) | Prohibited substance; no therapeutic use recognized[2] |
| International | Schedule I (UN Convention on Psychotropic Substances, 1971) | Parties required to prohibit use except for scientific and very limited medical purposes |
Legal status changes frequently and varies by jurisdiction. This information is not legal advice. Verify current laws in your jurisdiction before making decisions based on this information.
Analog act considerations
In the United States, MDA is specifically scheduled — no structural analog act invocation is needed. Novel MDA analogs not specifically listed may fall under the Federal Analogue Act if sold for human consumption and substantially similar in structure or effect. The lysine prodrug of MDA studied in the 2026 Basel trial[5] converts to MDA in the body and would likely be treated as an MDA analog under federal law.
references
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]